MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- AUROBINDO PHARMA - MYLAN (US)
AUROBINDO PHARMA vs MYLAN (US) - Comparison Results
AUROBINDO PHARMA Change
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 AUROBINDO PHARMA  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AUROBINDO PHARMA Mar-19 |
MYLAN Dec-18 |
AUROBINDO PHARMA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 830 | 3,495 | - | |
| Low | Rs | 527 | 1,924 | - | |
| Sales per share (Unadj.) | Rs | 333.9 | 1,608.1 | - | |
| Earnings per share (Unadj.) | Rs | 40.4 | 43.7 | - | |
| Cash flow per share (Unadj.) | Rs | 51.8 | 344.8 | - | |
| Dividends per share (Unadj.) | Rs | 2.50 | 0 | - | |
| Dividend yield (eoy) | % | 0.4 | 0 | - | |
| Book value per share (Unadj.) | Rs | 237.1 | 1,739.7 | - | |
| Shares outstanding (eoy) | m | 585.91 | 514.50 | - | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 2.0 | 1.7 | 120.6% | |
| Avg P/E ratio | x | 16.8 | 62.0 | 27.1% | |
| P/CF ratio (eoy) | x | 13.1 | 7.9 | 166.8% | |
| Price / Book Value ratio | x | 2.9 | 1.6 | 183.8% | |
| Dividend payout | % | 6.2 | 0 | - | |
| Avg Mkt Cap | Rs m | 397,569 | 1,393,882 | 28.5% | |
| No. of employees | `000 | 17.9 | 35.0 | 51.0% | |
| Total wages/salary | Rs m | 25,849 | 0 | - | |
| Avg. sales/employee | Rs Th | 10,956.9 | 23,639.1 | 46.4% | |
| Avg. wages/employee | Rs Th | 1,447.7 | 0 | - | |
| Avg. net profit/employee | Rs Th | 1,324.3 | 641.9 | 206.3% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 195,636 | 827,370 | 23.6% | |
| Other income | Rs m | 1,553 | 0 | - | |
| Total revenues | Rs m | 197,189 | 827,370 | 23.8% | |
| Gross profit | Rs m | 39,519 | 214,093 | 18.5% | |
| Depreciation | Rs m | 6,680 | 154,916 | 4.3% | |
| Interest | Rs m | 2,626 | 39,794 | 6.6% | |
| Profit before tax | Rs m | 31,767 | 19,383 | 163.9% | |
| Minority Interest | Rs m | 27 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -881 | 0 | - | |
| Tax | Rs m | 7,269 | -3,084 | -235.7% | |
| Profit after tax | Rs m | 23,645 | 22,467 | 105.2% | |
| Gross profit margin | % | 20.2 | 25.9 | 78.1% | |
| Effective tax rate | % | 22.9 | -15.9 | -143.8% | |
| Net profit margin | % | 12.1 | 2.7 | 445.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 153,645 | 462,003 | 33.3% | |
| Current liabilities | Rs m | 120,429 | 336,851 | 35.8% | |
| Net working cap to sales | % | 17.0 | 15.1 | 112.2% | |
| Current ratio | x | 1.3 | 1.4 | 93.0% | |
| Inventory Days | Days | 135 | 84 | 161.8% | |
| Debtors Days | Days | 64 | 93 | 68.3% | |
| Net fixed assets | Rs m | 103,909 | 160,496 | 64.7% | |
| Share capital | Rs m | 586 | 441 | 133.0% | |
| Net worth | Rs m | 138,908 | 895,063 | 15.5% | |
| Long term debt | Rs m | 1,800 | 966,060 | 0.2% | |
| Total assets | Rs m | 264,544 | 2,400,907 | 11.0% | |
| Interest coverage | x | 13.1 | 1.5 | 880.7% | |
| Debt to equity ratio | x | 0 | 1.1 | 1.2% | |
| Sales to assets ratio | x | 0.7 | 0.3 | 214.6% | |
| Return on assets | % | 9.9 | 2.6 | 383.0% | |
| Return on equity | % | 17.0 | 2.5 | 678.2% | |
| Return on capital | % | 23.8 | 3.2 | 749.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 16,220 | 171,928 | 9.4% | |
| From Investments | Rs m | -28,768 | -88,868 | 32.4% | |
| From Financial Activity | Rs m | 19,191 | -80,094 | -24.0% | |
| Net Cashflow | Rs m | 6,656 | 1,424 | 467.3% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 73.42 Rs / USD
Compare AUROBINDO PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare AUROBINDO PHARMA With: STRIDES PHARMA SCIENCE LUPIN FULFORD INDIA NOVARTIS SUVEN LIFE SCIENCES
Today's Market
Indian Share Markets Open Higher; JSW Steel & Tata Steel Top Gainers(09:30 am)
Asian share markets edged higher today as investors shrugged off concerns that stocks may have rallied too far too fast in the past year.
Related Views On News
AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)
Sep 15, 2020 | Updated on Sep 15, 2020For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)
Jun 5, 2020 | Updated on Jun 5, 2020For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Nov 6, 2019 | Updated on Nov 6, 2019Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
More Views on NewsMost Popular
It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)
Feb 25, 2021In this video, I'll show you how to get started on the path to daily trading profits.
I Believe the Investment of the Year Will Be...
Feb 19, 2021In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.
The Hidden Tesla in My Great Indian Wealth Project (Profit Hunter)
Feb 23, 2021An Indian company founded three decades ago in a garage caught my attention...
More
